Medical/Pharmaceuticals

Cognivia Secures Strategic 15.5M€ Funding to Empower Drug Development with AI-ML Solutions

Using patient personality traits to pioneer a new era in clinical research. MONT-SAINT-GUIBERT, Belgium, April 18, 2024 /PRNewswire/ -- Cognivia, an innovative AI company dedicated to reshaping pharmaceutical and biotech clinical research through cutting edge AI-ML algorithms, proudly announces a...

2024-04-18 21:00 2433

YS Biopharma Granted Phase I Clinical Trial License of Therapeutic Chronic Hepatitis B Virus Vaccine

GAITHERSBURG, Md., April 18, 2024 /PRNewswire/ -- YS Biopharma Co., Ltd. (Nasdaq: YS) ("YS Biopharma" or the "Company"), a global biopharmaceutical company dedicated to discovering, developing, manufacturing, and delivering new generations of vaccines and therapeutic biologics for infectious dise...

2024-04-18 20:00 1623

European Wellness Leads Pioneering Down Syndrome Research at Heidelberg University

HEIDELBERG, Germany, April 18, 2024 /PRNewswire/ -- The European Wellness Biomedical Group (EWBG), in collaboration with the European Wellness Academy (EWA), the Baden Research Lab, and Heidelberg University, has announced substantial advances in Down Syndrome research, revealing new neuroanatomi...

2024-04-18 16:17 1776

Siriraj Hospital Shines Spotlight on TAVI Procedure as Alternative for High-Risk Patients Requiring Aortic Valve Replacement

BANGKOK, April 18, 2024 /PRNewswire/ -- Siriraj Hospital, a leading healthcare institution inThailand, stands at the forefront of aortic valve disease treatment with Transcatheter Aortic Valve Implantation (TAVI). The minimally invasive procedure significantly reduces surgical trauma and post-sur...

2024-04-18 15:01 2269

TaiGen Successfully Completes TG-1000 Phase III Study

TAIPEI, April 17, 2024 /PRNewswire/ -- TaiGen Biotechnology Company, Limited ("TaiGen") announces today that the business partner, Joincare Pharmaceutical, has completed the unblinding of influenza antiviral TG-1000 phase III study. Preliminary data shows that the median time to alleviation of al...

2024-04-18 11:03 1550

Mini brains and lab-on-a-chip wearables: Jumar Bioincubator officially begins its mission to build "Australia's next CSL"

MELBOURNE, Australia, April 18, 2024 /PRNewswire/ -- Australia's newest biotech incubatorJumar Bioincubator has officially opened its doors and revealed the first 16 innovative early-stage ventures to take up residency in its much-awaitedMelbourne-based facility at an ...

2024-04-18 11:00 2079

Datasea Secures Combined $15 Million with its Second Sales Contract for Acoustic Products

BEIJING, April 17, 2024 /PRNewswire/ -- Datasea Inc. (Nasdaq: DTSS) ("Datasea" or the "Company"), a digital technology company incorporated inNevada, dedicated to innovative business in acoustic high tech and 5G-Artificial Intelligence ("AI") multimodal communication technology inthe United State...

2024-04-17 22:00 1561

Henlius Releases 2023 ESG Report: Pursuing Sustainable Development with Patient-centricity

SHANGHAI, April 17, 2024 /PRNewswire/ -- On April 17, 2024, Henlius (2696.HK) released its 2023 Environmental, Social and Governance (ESG) report (hereinafter referred to as "ESG report" or "report"). The report comprehensively discloses the Company's initiatives and achievements in promoting is...

2024-04-17 20:32 1805

Q1 2024 Revenue and Business Update

MELBOURNE, Australia, April 17, 2024 /PRNewswire/ -- Telix Pharmaceuticals Limited (ASX: TLX, Telix, the Company) today provides an update on its revenue and operational performance for the quarter ended31 March 2024 (Q1 2024). Summary: Q1 2024 financial performance  The Company reports unaudi...

2024-04-17 15:05 2013

World Hemophilia Day 2024"Equitable access for all: recognizing all bleeding disorders"

MONTREAL, April 17, 2024 /PRNewswire/ -- On April 17, 2024, the global bleeding disorders community will come together to celebrate World Hemophilia Day. The theme of the event this year is "Equitable access for all: recognizing all bleeding disorders". The World Federation of Hemophilia (WFH) vi...

2024-04-17 15:00 1586

GILEAD SCIENCES JOIN FORCES WITH WORLD HEPATITIS ALLIANCE AND EXPERTS TO AWARD US$4 MILLION ALL4LIVER GRANT FOR VIRAL HEPATITIS ELIMINATION BY 2030, INCLUDING TWO INNOVATIVE INITIATIVES IN ASIA

— Gilead Awards US$4 Million Globally (Excluding the United States) Through the Gilead ALL4LIVER Grant — – World Hepatitis Alliance Supports Global Expansion of Gilead ALL4LIVER Grant by Joining Grant Review Committee – — Vietnamese Organizations Institute of Gastroenterology and Hepatology and ...

2024-04-17 14:03 2067

GILEAD SCIENCES JOIN FORCES WITH WORLD HEPATITIS ALLIANCE AND EXPERTS TO AWARD US$4 MILLION ALL4LIVER GRANT FOR VIRAL HEPATITIS ELIMINATION BY 2030, INCLUDING TWO COMMUNITY LED INITIATIVES IN ASIA

— Gilead Awards US$4 Million Globally (Excluding the United States) Through the Gilead ALL4LIVER Grant — – World Hepatitis Alliance Supports Global Expansion of Gilead ALL4LIVER Grant by Joining Grant Review Committee – — Indian Organizations Chennai Liver Foundation and FIND Receive the Grant t...

2024-04-17 11:22 1899

SCG CELL THERAPY AND A*STAR LAUNCH JOINT LABS WITH COLLABORATION NEARING S$30 MILLION TO ADVANCE iPSC TECHNOLOGY TOWARDS SCALABLE GMP MANUFACTURING OF CELLULAR IMMUNOTHERAPIES

* Collaboration aims to develop scalable GMP-grade iPSC manufacturing processes and therapeutic candidates to facilitate research leading to translation of novel cellular immunotherapies. * Launch of the joint labs builds on existing license, research collaboration and Memorandum of Understan...

2024-04-17 10:00 1911

Kind Pharmaceuticals Announces Settlement

HANGZHOU, China, April 16, 2024 /PRNewswire/ -- Today, Hangzhou Andao Pharmaceutical Ltd. and Kind Pharmaceuticals LLC ("Kind Pharmaceuticals"), together with its Chief Executive Officer Dr.Dong Liu and Chief Scientific Officer Dr.Shaojiang Deng, announced a resolution of their recent dispute wit...

2024-04-17 00:17 2256

Mabwell Releases Preclinical Study Results of Multiple Innovative Drugs Released at the 2024 AACR Annual Meeting

SHANGHAI, April 16, 2024 /PRNewswire/ -- Mabwell (688062.SH), an innovation-driven biopharmaceutical company with entire industry chain, presented the preclinical research findings of three potential novel drug candidates in poster format at the American Association for Cancer Research (AACR) An...

2024-04-16 22:00 1728

CSafe Elevates Cell and Gene Therapy Transport with Reusable Cryogenic Solution

MONROE, Ohio, April 16, 2024 /PRNewswire/ -- CSafe, an active and passive temperature-controlled shipping solutions provider for the biopharmaceutical industry, proudly announces the launch of a new line of cryogenic multi-use dewars for the cell and gene therapy market. The progressive technolog...

2024-04-16 20:47 1867

YS Biopharma to Report First Nine Months of Fiscal Year 2024 Financial Results on April 19, 2024

GAITHERSBURG, Md., April 16, 2024 /PRNewswire/ -- YS Biopharma Co., Ltd. (NASDAQ: YS) ("YS Biopharma" or the "Company"), a global biopharmaceutical company dedicated to discovering, developing, manufacturing, and delivering new generations of vaccines and therapeutic biologics for infectious dise...

2024-04-16 20:00 2011

CryptoLab Signs a Contract to Supply Cutting-Edge Homomorphic Encryption Technology to Macrogen

SEOUL, South Korea, April 16, 2024 /PRNewswire/ -- CryptoLab, a pioneer of fully homomorphic encryption (FHE) technology has announced the signing of a three-year supply contract with Macrogen, Korea's largest genetic data analysis company. This landmark agreement was a huge milestone of FHE tech...

2024-04-16 20:00 966

Wingderm® Shines Bright in the U.S.A., Continuously Expanding the Local Business Network

BALTIMORE, April 16, 2024 /PRNewswire/ -- Wingderm®, a medical aesthetic device service provider that offers comprehensive aesthetic solutions, recently concluded its successful participation in the AAD (American Academy of Dermatology) Annual Meeting in March and the ASLMS (American Society for ...

2024-04-16 17:22 993

Korea Zinc announces non-renewal of sulfuric acid consignment contract with Young Poong

* The consignment of sulfuric acid originated from Young Poong's Seokpo Smelter adds to the operational risks for Korea Zinc * Young Poong has passed the costs and risks associated with sulfuric acid management to Korea Zinc while backlash from the local community adds to the burden * Addit...

2024-04-16 13:48 1091
1 ... 73747576777879 ... 610

Week's Top Stories